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Model Parameter Estimation and
Uncertainty Analysis: A Report of the
ISPOR-SMDM Modeling Good Research
Practices Task Force Working Group–6
Andrew H. Briggs, DPhil, Milton C. Weinstein, PhD, Elisabeth A. L. Fenwick, PhD,
Jonathan Karnon, PhD, Mark J. Sculpher, PhD, A. David Paltiel, PhD, on Behalf of
the ISPOR-SMDM Modeling Good Research Practices Task Force
A model’s purpose is to inform medical decisions and
health care resource allocation. Modelers employ quantita-
tive methods to structure the clinical, epidemiological, and
economic evidence base and gain qualitative insight to
assist decision makers in making better decisions. From
a policy perspective, the value of a model-based analysis
lies not simply in its ability to generate a precise point esti-
mate for a specific outcome but also in the systematic
examination and responsible reporting of uncertainty sur-
rounding this outcome and the ultimate decision being ad-
dressed. Different concepts relating to uncertainty in
decision modeling are explored. Stochastic (first-order)
uncertainty is distinguished from both parameter (second-
order) uncertainty and from heterogeneity, with structural
uncertainty relating to the model itself forming another
level of uncertainty to consider. The article argues that
the estimation of point estimates and uncertainty in param-
eters is part of a single process and explores the link
between parameter uncertainty through to decision uncer-
tainty and the relationship to value-of-information analy-
sis. The article also makes extensive recommendations
around the reporting of uncertainty, both in terms of deter-
ministic sensitivity analysis techniques and probabilistic
methods. Expected value of perfect information is argued
to be the most appropriate presentational technique, along-
side cost-effectiveness acceptability curves, for representing
decision uncertainty from probabilistic analysis. Key
words: uncertainty analysis; sensitivity analysis; heteroge-
neity; value of information; guidelines. (Med Decis Making
2012;32:722–732).
A new Good Research Practices in Modeling TaskForce was constituted by the ISPOR Board of
Directors in 2010, and the Society for Medical
Decision Making was invited to join the effort. This
paper, along with six others,1-6 is part of a series
commissioned by the Task Force.
INTRODUCTION
This report adopts the Task Force’s view that
a model’s purpose is to inform medical decisions
andhealth care resource allocation.Modelers employ
quantitative methods to structure the clinical,
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epidemiological, and economic evidence base and
gain qualitative insight to assist decision makers in
making better decisions. From a policy perspective,
a model-based analysis’s value lies not simply in its
ability to generate a precise point estimate for a spe-
cific outcome but also in the systematic examination
and responsible reporting of uncertainty surrounding
this outcome and the ultimate decision being
addressed. These are the hallmarks of good modeling
practice.
The extent to which an uncertainty analysis can be
considered fit for purpose in part depends on the
decision(s) the modeling seeks to support. Uncer-
tainty analysis can serve 2main purposes: assess con-
fidence in a chosen course of action and ascertain the
value of collecting additional information to better
inform the decision.
Manymodels are designed to help decisionmakers
maximize a given outcome (e.g., cases identified in
a screening model, or quality-adjusted life-years, in
a cost-effectiveness model), subject, perhaps, to one
or more limiting constraints (such as a fixed budget).
The model generates point estimates of the outcome
for each possible course of action; the ‘‘best’’ choice
is the one that maximizes the outcome subject to the
constraint. If the decision maker has to make
a resource allocation decision now, has no role in
commissioning or mandating further research, and
cannot delay the decision or review it in the future,
then the role of uncertainty analysis is limited and
the decision should be based only on expected values
(although some commentators have argued that for
nonlinear models, probabilistic sensitivity analysis
[PSA] is required to generate appropriate expected
values7). Nevertheless, decision makers may want
to gauge confidence in the best choice’s appropriate-
ness by exploring its robustness to changes in the
model’s inputs.
Increasingly, models are developed to guide deci-
sions of particular bodies (e.g., organizations respon-
sible for deciding whether to reimburse a new
pharmaceutical). Such decision makers who have
the authority to delay decisions or review them later,
based on research they commission or mandate,
should be interested not just in expected cost-effec-
tiveness but also in a thorough uncertainty analysis
and the value of additional research. Such informa-
tion, as well as assessments of factors such as the
costs of reversing a decision shown to be suboptimal
as further information emerges, and the cost of
research and likelihood of undertaking it, can
influence the array of decisions available. Thus,
uncertainty analysis conveys not only qualitative
information about the critical uncertainties sur-
rounding a decision but also quantitative information
about the decision maker’s priorities in allocating
resources to further research.
Manymodels are developed for general dissemina-
tion,without a specific decisionmaker inmind. Such
models could inform a range of decision makers with
varying responsibilities. Here, there is a case for
undertaking a full uncertainty analysis, thus allowing
different decision makers to take from the analysis
what they require given the decisions with which
they are charged.
Best Practices
VI-1 The systematic examination and responsible
reporting of uncertainty are hallmarks of goodmodel-
ing practice. All modeling studies should include an
uncertainty assessment as it pertains to the decision
problem being addressed.
VI-2 The decision maker’s role should be considered
when presenting uncertainty analyses. The analytic
perspective description should include an explicit
statement regarding what is assumed about the deci-
sion makers’ power to delay or review decisions and
to commission or mandate further research.
BACKGROUND AND TERMINOLOGY
It is important to be precise concerning the termi-
nology used in this article, which is sometimes
confused in the literature (reflecting the multidisci-
plinary nature of decision modeling in health care).
In particular, stochastic (first-order) uncertainty is
distinguished from both parameter (second-order)
uncertainty and from heterogeneity. Furthermore,
each concept is argued to have an analogous form
within a regression-type model in statistics. As in
regression analysis, the structural uncertainty asso-
ciatedwith themodel itself must also be considered.
Table 1 summarizes the concepts used here and pre-
ferred terminology, lists other terms used, and pro-
vides the link to statistical regression.
The term parameter uncertainty is not the same as
the uncertainty around the realization of individual
events or outcomes.This stochastic uncertainty relates
to the fact that individuals facing the same probabili-
ties and outcomes will experience the effects of a dis-
ease or intervention differently, just as a fair coin
might come up heads or tails on any given toss (e.g.,
UNCERTAINTY ANALYSIS
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the first patient in a sample might respond to a treat-
ment but thenextmaynot, the firstmaynot experience
an adverse effect but the secondmay, the firstmay stay
in hospital for 2 days and the second for 3). Parameter
uncertainty (second-order uncertainty) relates to the
fact that the probabilities that govern outcomes are
themselves uncertain because they are estimated
quantities (e.g., 100 tosses of a fair coinwill not always
lead to 50 realizations of ‘‘heads’’ and 50 ‘‘tails’’). Esti-
matesof theprobability of ‘‘heads’’ basedon100obser-
vations are uncertain. The sample size informing that
estimate and variance in the data contribute to deter-
mining the parameter uncertainty. Parameter uncer-
tainty also arises from the existence of multiple,
conflicting studies; problems with a source study’s
internal or external validity; generalizability from
a study to a real-world setting; and lack of empirical
data. Although these 2 types of uncertainty are clearly
linked, uncertainty about actual outcomes for individ-
uals differs from uncertainty surrounding population
parameter values (e.g., the response probability,
adverse event probability, or mean length of hospital
stay). The distinction is analogous to the difference
between standard deviation (estimate of how individ-
ual observations within a sample vary) and standard
error (precision of an estimated quantity).
Parameter uncertainty may be represented via
deterministic sensitivity analysis (DSA) or via PSA.
In a DSA, parameter values are varied manually to
test the sensitivity of the model’s results to specific
parameters or sets of parameters. In a PSA, (prefera-
bly) all parameters are varied simultaneously, with
multiple sets of parameter values being sampled
from a priori–defined probability distributions. The
outputs from a PSA may inform several different
forms of analysis, including confidence intervals,
cost-effectiveness planes (showing the distributions
of costs and effects for each evaluated technology
or service), cost-effectiveness acceptability curves
(showing the probability of cost-effectiveness for
each option), and value-of-information analyses.
The latter involve the estimation of the expected
value of perfect information (EVPI), which may be
estimated for the model as a whole or for specific
parameters or sets of parameters (expected value of
partial perfect information [EVPPI]).
Further adding to the confusion between first- and
second-order (parameter) uncertainty is use of variabil-
ity to refer to the former but also todifferences inparam-
eter values across patients or patient subgroups.
Heterogeneity refers to the extent to which between-
patient variability can be explained by patients’ charac-
teristics (e.g., age- and sex-specific mortality). Its rele-
vance lies in the identification of subgroups for whom
separate cost-effectiveness analyses should be under-
taken. Such analyses may inform alternative decisions
regarding the service provision to each subgroup or
contribute to aweightedanalysis of the aggregate group.
An analogy is a simple regression model of the
form
Y5Xb1e;
where an outcome variable Y depends on covariates
X. The vector of coefficients b represents the model
parameters and is estimated with uncertainty repre-
sented by the coefficients’ standard error from the fit-
ted regression. The extent to which the predicted
Table 1 Uncertainty for Decision Modeling: Concepts and Terminology
Preferred Term Concept
Other Terms
Sometimes Employed
Analogous
Concept in Regression
Stochastic uncertainty Random variability in outcomes
between identical patients
Variability; Monte Carlo
error; first-order uncertainty
Error term
Parameter uncertainty The uncertainty in estimation
of the parameter of interest
Second-order uncertainty Standard error of
the estimate
Heterogeneity The variability between patients
that can be attributed to
characteristics of those patients
Variability; observed or
explained heterogeneity
Beta coefficients
(or the extent to
which the dependent
variable varies by patient
characteristics)
Structural uncertainty The assumptions inherent in the
decision model
Model uncertainty The form of the regression
model (e.g., linear,
log-linear, etc.)
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values ( Y) vary with known covariates X represents
heterogeneity, and the stochastic error term e repre-
sents unexplained variability, whichwe call stochas-
tic uncertainty.
Just as a linear regression imposes a structural rela-
tionship between independent and dependent varia-
bles, so a decision-analytic model is characterized by
assumptions reflected in its structure but not formally
expressed numerically (e.g., types of adverse events
included, duration of treatment effects, time depen-
dency of probabilities, and prognostic implications of
surrogate endpoints or clinical events). Although these
structural assumptions are not typically formally quan-
tified, it is uncertain whether they express reality accu-
rately. As such, and analogously with statistical
modeling, any representation of uncertainty in a deci-
sionmodel is conditional on its structural assumptions.
Therefore, in principle, the structural characteristics
are a further level of uncertainty to be considered.
Although a model’s overall structure results from
many assumptions and analytic decisions, it is useful
to distinguish 2 broad categories of models that reflect
both the underlying structure and relate to the uncer-
tainty concepts outlined above. Patient-level stochas-
tic simulations (e.g., discrete-event simulations3 and
state-transition microsimulations2) are structured
around events occurring at the individual level and
requiring simulation of numerous virtual patients.
For these models, assessment of parameter uncer-
tainty requires elimination of stochastic uncertainty
(sometimes called Monte Carlo error). In cohort mod-
els, parameter uncertainty can be addressed without
concern for stochastic uncertainty.
Methodological uncertainty has been identified as
a specific type8,9 that can be as important as parame-
ter uncertainty.10 In common with others,9,11 we
think a reference case should be applied. Neverthe-
less, disagreement about appropriate methodology
may be a reason to undertake sensitivity analysis.
Best Practices
VI-3 Terminology to describe concepts relating to
parameter estimation and representation of uncer-
tainty varies within the health care decision-modeling
field and in comparison to related fields. Authors
should be aware of this and seek to carefully define
their use of terminology to avoid potential confusion.
PARAMETER ESTIMATION AND UNCERTAINTY
ANALYSIS
Allmodels have parameters thatmust be estimated.
In doing so, analysts should conform to evidence-
based medicine principles (e.g., seek to incorporate
all evidence, rather than selectively picking a single
source; use best-practice methods to avoid potential
biases, as when estimating treatment effectiveness
from observational sources; employ formal evidence
synthesis techniques12,13). Uncertainty analysis is
equally integral: The steps taken to estimate a parame-
ter link directly with those necessary to conduct
uncertainty analysis. Standard statistical methods for
estimation generate a point estimate together with
some measure of precision, such as standard errors
or 95% confidence intervals. This is true whether
these methods are implemented within a uni- or mul-
tivariable framework, although the latter will also pro-
vide a measure of covariance between estimated
parameters. Consequently,whetherprimarydata sour-
ces are used to estimate input parameters or informa-
tion derives from one or more secondary source, the
estimation generates a point estimate, a measure of
precision, and, potentially, one of covariance. These
types of information from estimation should feed
directly into the uncertainty analysis.
This is true whatever the uncertainty analysis’s
technical specification. For a 1-way DSA, it is neces-
sary to specify the parameter’s point estimate and
a defensible range; these may be taken directly from
the estimation process, with the latter based, for
example, on a 95% confidence interval. A 2-way
uncertainty analysis will be more useful if informed
by the covariance between the 2 parameters of inter-
est or on the logical relationship between them (e.g.,
a 2-way uncertainty analysis might be represented
by the control intervention event rate and the hazard
ratio with the new treatment).
Representation of uncertainty depends on the
uncertainty analysis planned. For DSA, an interval
estimate representing beliefs about the parameter’s
plausible range is required. For PSA, a distribution
is specified via its parameters.
Best Practices
VI-4 All decision models have parameters that need
to be estimated. Populating models with parameter
estimates should conform to evidence-based medi-
cine principles.
Consistency of Approach between Deterministic
and Probabilistic Uncertainty Analysis
Uncertainty estimates for parameters estimated (or
estimable) from data should be consistent with standard
statistical approaches. The underlying distributional
UNCERTAINTY ANALYSIS
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assumption used to calculate the 95% confidence inter-
val can be the basis for an uncertainty analysis distribu-
tional assumption. One exception is when taking
a formal Bayesian approach involving subjective prior
information, where the standard distributional assump-
tion relates to the data likelihood combined with the
prior information to form the posterior density. In this
case, consistency between DSA and the fully Bayesian
probabilistic approach would be retained if the DSA
interval estimate were based on the Bayesian posterior’s
95% highest density region.14
Some uncertainty analyses do not require formal
ascertainment of parameter uncertainty. These
include threshold analysis, in which the parameter’s
value needed to change the decision is identified.
This is closely linked to ‘‘even if’’ approaches, which
identify extreme parameter values that still do not
change the decision—with the implication that these
parameters are unlikely to influence the decision.
Such analysesmay be sufficient if there is little decision
uncertainty given reasonable assumptions about param-
eter uncertainty.Another formnot requiringuncertainty
estimation is identification of the quantitative relation-
shipsbetween inputs andoutputs (e.g., itmight bedeter-
mined that a 10% increase in a particular parameter’s
value leads to a 20% increase in expected effectiveness
and 5%decrease in expected cost). This sort of analysis
is unlikely to be sufficient because a parameterwith low
sensitivity, but highly uncertain, could easily havemore
impact on the model outputs than a more sensitive
parameter but estimated more precisely. Therefore,
completely arbitrary analyses, such as the effect on out-
puts of varying each input by650%, is not recommen-
ded as a representation of uncertainty.
Best Practices
VI-5 Whether employing deterministic methods
(point estimate and range) or probabilistic methods
(parameterized distribution), the link to the underly-
ing evidence base should be clear.
VI-6Although completely arbitrary analyses, such as
presentation of the effect on outputs of varying inputs
by 650%, can be used as a measure of sensitivity,
such analyses should not be used to represent
uncertainty.
Estimation and Choice of Distribution for PSA and
Interval Estimation
If there is much information available to inform
a parameter’s estimate, then by the central limit
theorem—the sampling distribution of the arithme-
tic mean will follow a normal distribution (with suffi-
cient sample size), whatever the data’s underlying
distribution—then the normal distribution can be
used in a PSA and a standard confidence interval in
a DSA. Consistency between each form of uncertainty
estimate is maintained because the arithmetic mean
and standard error inform both the parameters of the
distribution and the confidence interval calculation.
Nevertheless, the reality of multiple data sources sug-
gests that reliance on a single study is likely to underes-
timate uncertainty. This suggests a broader uncertainty
analysis than based on study data alone, leaving open
some subjective assessment for ensuring appropriate
representation of uncertainty, even where single large
studies are available for estimatingparameters and their
associated uncertainty.
The general principle remains that assumptions
for specifying the distribution and/or defining the
interval for uncertainty analysis should follow stan-
dard statistical methods (e.g., beta distributions are
a natural match for binomial data; gamma or log nor-
mal for right skew parameters; log normal for relative
risks or hazard ratios; logistic for odds ratios15). These
distributions can be used directly in PSA or to define
the interval (plausible range) for a DSA.
Sometimes there is very little information on
a parameter because either there are very few studies
informing the estimation or there are no data and
expert opinion must be relied on. Here, it is impera-
tive that uncertainty related to such estimates be fully
explored. A conservative approach should be adop-
tedwith an appropriately broad range of possible esti-
mates elicited from each expert, reflected in how
opinions are combined across experts and incorpo-
rated into the uncertainty analysis. On no account
should parameters be excluded from an uncertainty
analysis on the grounds that ‘‘there is not enough
information to estimate uncertainty.’’ Continuous
distributions providing a realistic portrayal of uncer-
tainty over the parameter’s theoretical range should
be favored in PSA. Hence, careful consideration
should be given to whether convenient-to-fit, but
implausible, distributions (e.g., uniform or triangu-
lar) should have any role in PSA. Formal methods
for eliciting probability distributions from experts
have been developed.16
Best Practices
VI-7 Use commonly adopted statistical standards for
point and interval estimation (e.g., 95% confidence
intervals or distributions based on agreed statistical
methods for a given estimation problem). Where
ISPOR-SMDM TASK FORCE
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departures from these standards are deemed neces-
sary (or no such standard exists), these should be jus-
tified.
VI-8 Where there is very little informationon aparam-
eter, adopt a conservative approach such that the
absence of evidence is reflected in a very broad range
of possible estimates. Never exclude parameters from
uncertainty analysis on the grounds that there is insuf-
ficient information to estimate uncertainty.
VI-9 Favor continuousdistributions that portrayuncer-
tainty realistically over the theoretical range of the
parameter. Careful consideration should be given to
whether convenient-to-fit but implausibledistributions
(such as the triangular) should have a role in PSA.
MULTIVARIATE ESTIMATION AND
CORRELATION
When regression is used to capture the effect of
subject characteristics on parameter estimates, the
dependent variable is a functional parameter of the
regression coefficients. Therefore, uncertainty in the
functional parameter can be defined in terms of
uncertainty (and correlation) in the coefficients.
The covariance matrix defines these uncertainties,
and the assumption of multivariate normality is
appropriate for the regression’s linear predictor.
These can be used to specify the interval for DSA or
as the basis for PSA.15
In PSA, parameters are typically not all indepen-
dent of one another. For example, if 2 uncertain
parameters are disease progression probabilities with
and without treatment, part of the uncertainty may
derive from doubts regarding the disease’s natural his-
tory and part from imprecise measurement of treat-
ment efficacy. The component related to natural
history would affect the progression probabilities
with or without treatment, whereas the component
related to efficacy would affect the relationship (e.g.,
relative risk) between progression probabilities with
and without treatment. It would be wrong to regard
the progression probabilities as coming from indepen-
dent distributions and conduct thePSAaccordingly. It
might be reasonable, however, to regard the natural
history progression probability and the risk reduction
with treatment as independent. Parameter distribu-
tions in this situation should be defined in a way
that makes it plausible that they are independent. In
this example, the baseline progression probability
and the relative risk reduction would be assigned
distributions in the PSA, with the on-treatment pro-
gression probability derived as their product. Where
this application of relative risks can result in out-of-
range parameters, consider switching to odds ratios.
Although this method of defining parameters in
away that inducesmutual independence offers a prac-
tical and sufficient approach inmany situations, more
sophisticated methods that explicitly quantify joint
distributions of correlated parameters may also be
considered.15
Best Practices
VI-10 Correlation among parameters should be consid-
ered. Jointly estimated parameters, such as those from
a regression analysis, will have direct evidence on cor-
relation, which should be reflected in the analysis.
Independently estimated parameters will have no
such evidence, but this should not necessarily lead to
an assumption of independence. Possible approaches
are to include a correlation coefficient as a parameter
where concern exists that an unknown correlation
could be important or to reparameterize the model so
that that the uncertain parameters can be reasonably
assumed to be independent.
CALIBRATION METHODS AND STRUCTURAL
UNCERTAINTY
There is emerging interest in calibration meth-
ods that combine knowledge over parameter
inputs, structure, and outputs (or calibration tar-
gets) to assist in ensuring consistency of inputs
and outputs. Common calibration targets include
overall and disease-specific mortality and event
incidence rates.
Bayesian (or multiparameter) evidence synthesis is
a calibration approachdeveloped inhealth technology
assessment using Markov chain Monte Carlo (MCMC)
via freely available WinBUGS software.13 This
approach involves specification of a structure com-
prising inputs and parameters that are functions of
multiple inputs, for which an external data source
exists.17 The MCMC estimates a joint set of posterior
distributions for the input parameters, based on the
functionalparameters: likelihood.Most appliedexam-
ples of this approach have involved relatively simple
structures. For more complex models, standard cali-
bration approaches can be applied to identify the
best fitting set of inputs, or multiple sets of values,
which can then form the basis for uncertainty analy-
sis.18–21 Steps in calibration include identifying cali-
bration targets, selecting individual and aggregated
UNCERTAINTY ANALYSIS
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measures of goodness-of-fit (GoF), defining the param-
eter space, selecting a search strategy, defining conver-
gence thresholds, and specifying a stopping rule.22
The use of calibration to estimate parameters or
adjust estimated values emphasizes the important
role model structure plays in defining the relation-
ship between inputs and outputs. Structural uncer-
tainty is frequently ignored, although it may have
a much greater impact on results than parameter
uncertainty.10 Recent approaches to this issue
have sought to parameterize structural uncertain-
ties into the model.23-25 This is trivial for nested
structures (e.g., a constant hazard function could
be replaced by a more flexible function) but is
much more challenging for nonnested structures,
which could require complete redesign/rebuilding
of the model. Although it may be feasible to inter-
nalize structural uncertainty by adding parameters
to the model, any given research team will be lim-
ited in the extent to which they can fully incorpo-
rate this form of uncertainty. In such situations,
analysts are encouraged to be as explicit as possible
regarding the structural assumptions that might
have an impact on the findings and suggest alterna-
tive assumptions that future modeling exercises
might employ.
Best Practices
VI-11Where uncertainties in structural assumptions
were identified in the process of conceptualizing and
building a model, those should be tested in uncer-
tainty analysis. Consideration should be given to
opportunities to parameterize these uncertainties
for ease of testing. Where it is impossible to perform
structural uncertainty analysis, it is important to be
aware that this uncertainty may be at least as impor-
tant as parameter uncertainty.
REPORTING UNCERTAINTY ANALYSES
Often, it is appropriate to report aspects of both
DSA and PSA (e.g., may report deterministic thresh-
old analysis for key parameters and PSA to convey
overall uncertainty). The guiding principle is that
the reporting method should be tailored to guide
the decision at issue.
When additional assumptions or parameter values
are introduced for purposes of uncertainty analysis
(e.g., distribution parameters for PSA, parameter
ranges for DSA), these should be disclosed and justi-
fied. Technical appendices are often appropriate for
this purpose. When calibration is used to derive
parameters, uncertainty around the calibrated values
should be reported, and this uncertainty should be
reflected in DSA, PSA, or both.
Reporting Deterministic Sensitivity Analysis (DSA)
Many methods may be used to convey how results
depend on individual parameters, multiple parame-
ters jointly, or model structure. One-way DSA may
be reported using a tornado diagram (Figure 1). The
horizontal axis is the outcome; along the vertical
axis, parameters are arrayed and horizontal bars rep-
resent the outcome range associated with the speci-
fied parameter’s range. The outcome point estimate
corresponding to base-case values is indicated by
a vertical line cutting through all horizontal bars.
Commonly, the longest bar (reflecting the parameter
generating the widest uncertainty) is placed at the
top, and the other bars are arrayed in descending
order of length. A tornado diagram should be accom-
panied by a legend or table indicating the upper and
lower bounds of values for each parameter, with their
justification in terms of the evidence base. A table
may be used instead of a tornado diagram or the
results ranges provide in the text of the report (e.g.,
the text might state that ‘‘the outcome ranged from
X to Y when parameter Z was varied from A to B’’).
It is important that the rangeA toB represents a defen-
sible range for parameter Z, not an arbitrary one.
Often, uncertainty in a parameter may be repre-
sented by several discrete values, instead of a contin-
uous range, sometimes called scenario analyses (e.g.,
evidence from clinical studies, utility surveys, or cost
data setsmay lead to different values). It is acceptable
to report alternative outcomes under each of these
Point Esmate
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Figure 1 Tornado diagram showing impact of uncertainty on the
outcome of a decision model
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discrete assumptions to complement other uncer-
tainty analysis.
Structural uncertainty may be represented deter-
ministically by reporting results under each set of
structural assumptions. Quantitative uncertainty
analysis may be embedded within structural uncer-
tainty analysis by reporting them separately under
each structural assumption.
In presenting 1-way uncertainty analysis, reporting
negative incremental cost-effectiveness ratios (ICERs)
should be avoided as they aremeaningless.26,27 Instead,
the ICER range should be limited to results correspond-
ing to positive incremental health consequences and
costs—quadrant I in the cost-effectiveness plane.
Results for which incremental costs are positive and
health consequences negative should be indicated
qualitatively as ‘‘dominated’’ and those with negative
incremental costs and positive health consequences
as ‘‘dominant.’’ ICERs corresponding to negative incre-
mental costs and health consequences—quadrant
III—should be distinguished from ICERs in quadrant I.
Results of 1-way threshold analyses are easily
reported in text (e.g., ‘‘The ICER remains less than Y
as long as the value of X is greater than A,’’ or ‘‘Alter-
native 1 dominates 2 if the value of Z is less than B’’).
Results of 2- and multiway uncertainty analysis
require graphical or tabular displays (Figure 2). The
axes represent possible values, and the quadrant is
partitioned into regions corresponding to various
ICERs, the boundaries representing specified ICER
thresholds, or thresholds of dominance. As in 1-
way analyses, it is important to specifywhich alterna-
tive dominates and which comparator is more effec-
tive and costly when an ICER threshold is
indicated. Three-way threshold analyses may be
superimposed on 2-way graphs by overlaying thresh-
old curves (Figure 3), but this often leads to visual
overload and confusion and will work only if the
third parameter can be represented as taking on dis-
crete values.
Threshold analyses are especially useful, perhaps
necessary, when reporting DSA involving 3 or more
comparators. In those situations, the relevant question
maybe, ‘‘Whichalternativeiscost-effectiveata threshold
of X?’’ To portray the answer for 2 parameters, partition
the quadrant to show which alternative is cost-effective
at various ICER thresholds and for different combina-
tions of parameters (Figures 4A and 4B). Results for dif-
ferent decision criteria (e.g., ICER thresholds or
dominance) are best presented in separate panels of
a graphical display.
When the base-case result of an analysis strongly
favors one alternative, a threshold analysismaybepre-
sentedas aworst-case or ‘‘even if’’ analysis (e.g., ‘‘Even
if the risk reduction is as low as X, the ICER remains
below Y,’’ or ‘‘Even if the relative risk reduction with
alternative A is as low as X and the cost of treatment
is as high asY, alternativeAdominatesB’’). Threshold
values can easily be combined with the tornado pre-
sentation by marking them on the horizontal bars.
Reporting Probabilistic Sensitivity Analysis (PSA)
When reporting a PSA, the specific distribution
(e.g., beta, normal, log-normal) as well as its parame-
ters should be disclosed. Sometimes it is feasible to
incorporate this information into the table listing
model parameters. If not, a table detailing the distri-
butionsmay be included in a technical appendix. Jus-
tification for the distributions chosen should be
provided. This may be directly from empiric data,
a full Bayesian evidence synthesis, or subjective. As
personal judgments need not correspond to the deci-
sion makers’ perceptions, alternative specifications
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Figure 3 Three-way threshold analysis.
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and parameters should be provided so users can
select the distributions most closely reflecting their
own judgments. A rule of reason applies in this
regard: Parameters that exert little leverage on the
overall uncertainty can be left as subjective.
Perhaps the best measure of uncertainty surround-
ing a particular decision in cost-effectiveness analy-
sis is the EVPI because this measure combines the
probability of incorrect decision making with the
consequential loss function.28 The higher the EVPI,
the larger the opportunity cost of an incorrect deci-
sion viewed at the point at which the uncertain deci-
sion is being made (i.e., the more costly is the
uncertainty). Total EVPI is commonly reported in
monetary terms, using net monetary benefit (an alter-
native is to express EVPI using net health benefit).
Because both net monetary and net health benefit
depend on the ICER threshold, EVPI should be
reported for specified ICER threshold(s) or in graphi-
cal form as a function of ICER thresholds (Fig 5).
EVPPI can be estimated to identify key parameters
and should be reported as for EVPI. Because of the likely
correlation between individual parameters in EVPPI, it
may be preferable to report values for groups of parame-
ters, which might also be the focus of future research
efforts.29,30 Expected value of sample information analy-
ses31 should be reported similarly but with the addi-
tional proviso that the factors governing the assumed
study from which sample information is obtained (e.g.,
sample size, individual-level or patient-level variation
in outcomes) must also be specified.
When a PSA is performed without an accompany-
ing value-of-information analysis, options for present-
ing results include cost-effectiveness acceptability
curves (CEACs) and distributions of netmonetary ben-
efit or net health benefit. When more than 2 interven-
tions are involved, CEACs for each should be plotted
on the same graph (Figure 6), with or without inclu-
sion of a cost-effectiveness acceptability frontier.
Reporting Uncertainty owing to Calibrated
Parameters
Whenmodel calibration is used to estimate param-
eters not directly observable from data, uncertainty
owing to the calibration process should be reported.
As for other model parameters, such reporting may
be either deterministic or probabilistic. Deterministic
reporting involves presentation of the range of cali-
brated input parameter values across the convergent
parameter sets and the resulting range of outputs
(e.g., ICERs). The results may be reported as discrete
point estimates or as a range.
Probabilistic calibration-related uncertainty can be
reported in many ways. If a formal Bayesian approach
to calibration is used, then the posterior distributions
of the calibrated parameters should be reported. If
a less formal approach to calibration is used, then a dis-
crete joint distribution of parameter estimates can be
generated based on all convergent input parameter
sets. The discrete distribution may assign equal proba-
bility to each resulting parameter value set, or probabil-
ity weights may be applied that reflect the relative GoF
of the component parameter sets.
Analogous to the reporting of structural uncer-
tainty, the results of separate calibration analyses
using alternative methodological approaches should
be reported under each discrete calibration process.
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Alternative approaches may include the objective
function used for evaluating GoF, the computational
process or algorithm used to identify convergent
parameter sets, and the importance weights attached
to different calibration targets.
Best Practices
VI-12 It is appropriate to report both deterministic
andprobabilistic uncertainty analyseswithin a single
evaluation. Tornado diagrams, threshold plots, or
simple statements of threshold parameter values are
all appropriate ways of reporting results from deter-
ministic sensitivity analyses.
VI-13 When additional assumptions or parameter val-
ues are introduced for purposes of uncertainty analyses,
these values should be disclosed and justified.
VI-14 When model calibration is used to derive
parameters, uncertainty around the calibrated values
should be reported and reflected in deterministic or
probabilistic sensitivity analyses or both.
VI-15 When the purpose of a PSA is to guide deci-
sions about acquisition of information to reduce
uncertainty, results should be presented in terms of
expected value of information.
VI-17 For economic studies, when a PSA is per-
formed without an accompanying expected value of
information analysis, options for presenting results
include CEACs and distributions of net monetary
benefit or net health benefit. When more than 2 com-
parators are involved, curves for each comparator
should be plotted on the same graph.
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